AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819
January 28, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
January 21, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference
January 07, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted,...
AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
January 06, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted,...
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event
January 05, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted,...
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
November 10, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...
AzurRx BioPharma Announces Formation of Scientific Advisory Board
October 21, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Globally recognized experts in cystic fibrosis and chronic pancreatitis care and research to support AzurRx in advancing the clinical development of MS1819 NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE)...
AzurRx BioPharma CEO Issues Letter to Shareholders
October 07, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
September 15, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic...
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
August 17, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Three clinical trial sites activated in Poland, with patient screening initiatedFollows activation of six clinical sites in the U.S. and dosing of first three patientsTopline data expected in Q1 2021 ...